1092942-82-9

Basic information

• Product Name: Imatinib-d8
• Synonyms: Imatinib-d8;Imatinib-d8 (as formate)
• CAS NO: 1092942-82-9
• Molecular Formula: C₂₉H₃₁N₇O
• Molecular Weight: 501.652034224
• Mol File: 1092942-82-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Imatinib-d8(CAS DataBase Reference)
• NIST Chemistry Reference: Imatinib-d8(1092942-82-9)
• EPA Substance Registry System: Imatinib-d8(1092942-82-9)

Safety Data

• Hazardous Substances Data: 1092942-82-9(Hazardous Substances Data)

Usage

Description

Imatinib-d8, also known as Labeled Imatinib, is a deuterated tyrosine kinase inhibitor. It is a stable isotope-labeled analog of Imatinib, which is a small molecule drug used to treat various cancers. Imatinib-d8 is characterized by the incorporation of deuterium atoms into its molecular structure, which provides enhanced stability and sensitivity in analytical techniques.

Uses

Used in Pharmaceutical Analysis:
Imatinib-d8 is used as an internal standard for the quantification of Imatinib by gas chromatography (GC) or liquid chromatography (LC) mass spectrometry. Its stable isotopic composition allows for accurate and precise measurement of Imatinib levels in biological samples, ensuring reliable results in pharmacokinetic and pharmacodynamic studies.
Used in COVID-19 Research:
Imatinib-d8 is a COVID-19-related research product, utilized in the investigation of the SARS-CoV-2 virus and its impact on human health. As a tyrosine kinase inhibitor, it may have potential applications in modulating the host's immune response to the virus, as well as interfering with viral replication and entry into host cells. Further research is needed to explore its efficacy and safety in the context of COVID-19 treatment.

Upstream product

• 917358-65-7 1-methyl-(2,2,3,3,5,5,6,6-d₈)piperazine 
• 404844-11-7 4-(chloromethyl)-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]-amino}phenyl)benzamide 

Relevant articles and documents

METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB

The invention relates to new processes for the manufacture of N-{5-[4-(4-methyl-piperazino- methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine of formula (I), new processes for the manufacture of metabolites of N-{5-[4-(4-methyl-piperazino-methyl)- benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine observed after administration of the compound to warm-blooded animals as well as to intermediates used in said processes. New starting materials as well as processes for the preparation thereof are likewise the subject of this invention. The processes described herein are especially suitable to furnish said compounds having isotopic labeling. The such obtained labeled compounds are in particular suitable to track and to investigate into the metabolism of N-{5-[4-(4-methyl- piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and its pharmaceutically acceptable salts in clinical and pre-clinical studies.